Seelos Therapeutics Management
Management criteria checks 3/4
Seelos Therapeutics' CEO is Raj Mehra, appointed in Jan 2019, has a tenure of 5.83 years. total yearly compensation is $1.73M, comprised of 34% salary and 66% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth $715.76. The average tenure of the management team and the board of directors is 4.5 years and 5.8 years respectively.
Key information
Raj Mehra
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 34.0% |
| CEO tenure | 5.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 4.5yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Seelos: Data This Year Is Critical
Oct 04Seelos wins Parkinson’s research grant for gene therapy program
Aug 24Seelos: FDA Action Makes It Highly Attractive
Dec 22Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains
Oct 01We're Hopeful That Seelos Therapeutics (NASDAQ:SEEL) Will Use Its Cash Wisely
Aug 18
Seelos: Superior Data, But Early Stage
Jun 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$4m |
| Mar 31 2024 | n/a | n/a | -US$27m |
| Dec 31 2023 | US$2m | US$587k | -US$38m |
| Sep 30 2023 | n/a | n/a | -US$51m |
| Jun 30 2023 | n/a | n/a | -US$81m |
| Mar 31 2023 | n/a | n/a | -US$73m |
| Dec 31 2022 | US$2m | US$562k | -US$74m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | n/a | n/a | -US$73m |
| Mar 31 2022 | n/a | n/a | -US$61m |
| Dec 31 2021 | US$16m | US$523k | -US$66m |
| Sep 30 2021 | n/a | n/a | -US$45m |
| Jun 30 2021 | n/a | n/a | -US$39m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$4m | US$475k | -US$19m |
| Sep 30 2020 | n/a | n/a | -US$23m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$21m |
| Dec 31 2019 | US$709k | US$438k | -US$51m |
Compensation vs Market: Raj's total compensation ($USD1.73M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Raj's compensation has been consistent with company performance over the past year.
CEO
Raj Mehra (64 yo)
5.8yrs
Tenure
US$1,726,476
Compensation
Dr. Raj Mehra, Ph D., J.D., serves as Chairman at Seelos Therapeutics, Inc. and serves as Chief Executive Officer, Director and President of Seelos Therapeutics, Inc. since January 24, 2019. He was an Inde...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Founder | 5.8yrs | US$1.73m | 0.33% $ 715.8 | |
| Chief Financial Officer | 3.2yrs | US$846.67k | 0.16% $ 336.1 | |
| Chief Communications Officer | 5.8yrs | no data | no data | |
| Head of Manufacturing & Technical Operations | no data | no data | no data | |
| Chief Medical Officer | no data | no data | no data | |
| Senior VP & Head of Clinical Operations | 2yrs | no data | no data |
4.5yrs
Average Tenure
Experienced Management: SEEL.Q's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Founder | 5.8yrs | US$1.73m | 0.33% $ 715.8 | |
| Independent Director | 3.2yrs | US$89.72k | 0.0021% $ 4.4 | |
| Independent Director | 11.7yrs | US$87.72k | 0.00023% $ 0.5 | |
| Independent Director | 5.8yrs | US$105.22k | 0% $ 0 |
5.8yrs
Average Tenure
62yo
Average Age
Experienced Board: SEEL.Q's board of directors are considered experienced (5.8 years average tenure).